The most promising drugs for alternative pharmacological PD treatments are Glucagon-like Peptide-1 (GLP1) agonists or dipeptidyl peptidase-4 enzyme (DPP4) inhibitors (also known as gliptins). This evidence concerns the gene DPP4 and Parkinson disease.